Image

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.

Description

Ecoendoscopy-guided choledochoduodenostomy (EUS-CDS) with a biliary lumen-apposing metal stent (LAMS) has been widely accepted as a second line treatment in cases of ERCP failure in malignant distal biliary obstruction (MDBO). Recent studies (DRAMBO and ELEMENT trial) compared EUS-CDS vs ERCP as a first line treatment in MDBO in palliative patients, showing similar clinical and techinal success and adverse events rate between both techniques, demonstrating that both procedures could be options for primary biliary drainage in unresectable MDBO.

Furthermore a recent clinical trial (BAMPI trial) has proven that the addition of a coaxial double pigtail (DPS) offers benefits in terms of safey and clinical success.

In the last years there has been an increasing interest for the EUS-guided gallblader drainage (EUS-GBD) in unresectable MDBO as an alternative for EUS-CDS, and recent studies and reviews have been reported with acceptable techinal and clinical success, but no clinical trial has been performed up to date.

Our hypothesis is that EUS-GBD may offer benefits in terms of safety over EUS-CDS, maintaining similar clinical and techinal success rates.

Eligibility

Inclusion Criteria:

  • Malignant distal biliary obstruction diagnosed in patient considered PALIATIVE with biliary drainage indication.
  • Consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory)
  • Patient capable of understanding and/or singning the informed consent.
  • Patient who understands the type of study and will comply with all follow-up tests throughout its duration

Exclusion Criteria:

  • Pregnancy or lactation.
  • Severe coagulation disorder: INR > 1.5 non correctable with plasma administration and/or platelet count < 50.000/mm3.
  • Previous cholecistectomy or gallblader perforation.
  • Tumoral obstruction of cystic duct.
  • Multiple liver metastases affecting more than 30% of the liver parenchyma
  • Distal malignant biliary strictures in patients considered resectable or borderline.
  • Benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum.
  • Patients with prior biliary stents or other biliary drainages (e.g., PTCD).
  • Altered intestinal anatomy due to prior surgery that prevents or hinders papillary access ______________ (e.g., gastric bypass, Billroth II, duodenal switch, Roux-en-Y).
  • Gastric outlet obstruction.
  • Situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture).
  • Patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available.
  • Patients incapable of maintaining follow-up appointments (lack of adherence).
  • Lack of informed consent.

Study details
    Malignant Biliary Obstruction
    Biliary Tract Neoplasms
    Pancreatic Cancer Non-resectable

NCT06375967

Hospital Universitari de Bellvitge

2 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.